Seres Therapeutics Inc (MCRB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Seres Therapeutics Inc stock (MCRB) is currently trading at $8.28. Seres Therapeutics Inc PE ratio is 9.66. Seres Therapeutics Inc PS ratio (Price-to-Sales) is 97.46. Analyst consensus price target for MCRB is $21.00. WallStSmart rates MCRB as Sell.
- MCRB PE ratio analysis and historical PE chart
- MCRB PS ratio (Price-to-Sales) history and trend
- MCRB intrinsic value — DCF, Graham Number, EPV models
- MCRB stock price prediction 2025 2026 2027 2028 2029 2030
- MCRB fair value vs current price
- MCRB insider transactions and insider buying
- Is MCRB undervalued or overvalued?
- Seres Therapeutics Inc financial analysis — revenue, earnings, cash flow
- MCRB Piotroski F-Score and Altman Z-Score
- MCRB analyst price target and Smart Rating
Seres Therapeutics Inc
📊 No data available
Try selecting a different time range
MCRB Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Seres Therapeutics Inc (MCRB)
MCRB trades 136% above its Graham fair value of $5.98, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Seres Therapeutics Inc (MCRB) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, profit margin. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Seres Therapeutics Inc (MCRB) Key Strengths (3)
Keeps $722 of every $100 in revenue as net profit
Trading at 1.76x book value, attractively priced
Solid profitability: $20 profit per $100 equity
Supporting Valuation Data
Seres Therapeutics Inc (MCRB) Areas to Watch (7)
PEG ratio is negative or unavailable
Losing money on operations
Revenue declining -93.40%, a shrinking business
Earnings declining -91.90%, profits shrinking
Very expensive at 97.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Seres Therapeutics Inc (MCRB) Detailed Analysis Report
Overall Assessment
This company scores 35/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.3/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Profit Margin, Price/Book, Return on Equity. Valuation metrics including Price/Book (1.76) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 19.60%, Profit Margin at 722.00%.
The Bear Case
The primary concerns are PEG Ratio, Operating Margin, Revenue Growth. Some valuation metrics including PEG Ratio (N/A), Price/Sales (97.46) suggest expensive pricing. Growth concerns include Revenue Growth at -93.40%, EPS Growth at -91.90%, which may limit upside. Profitability pressure is visible in Operating Margin at -4424.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 19.60% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -93.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MCRB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MCRB's Price-to-Sales ratio of 97.46x trades 42% below its historical average of 169.14x (0th percentile). The current valuation is 60% below its historical high of 245.36x set in Mar 2026, and 0% above its historical low of 97.46x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~225.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Seres Therapeutics Inc (MCRB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Seres Therapeutics Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 789,000 with 93% decline year-over-year. Profit margins are strong at 722.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 1960.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Spending 1481% of revenue (12M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 93% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -15M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Seres Therapeutics Inc.
Bottom Line
Seres Therapeutics Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Seres Therapeutics Inc(MCRB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.